All In MedTech

Device Trial Radar · NCT00967746

An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)

A Randomized, Multicenter, Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Doses of an Etonogestrel-releasing Medicated Intrauterine System (ENG-MIUS) Versus a Copper-releasing Intrauterine Device (IUD)

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Nov 2009

Primary completion

Nov 2010

Study completion Jul 2011

Sponsor

Lead sponsor
Organon and CoNot on our public-company list
Sponsor type
Industry
First posted
Aug 28, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, active-controlled, parallel-group, multicenter, single-blind trial of three different doses of etonogestrel releasing medicated intrauterine systems (ENG-MIUS) in healthy parous women in need for contraception. The primary trial objective is to explore safety and acceptability of three doses of an ENG-releasing medicated intrauterine system (ENG-MIUS) as compared to Multiload-cu 375®.

Conditions

  • Contraception

Interventions

  • Etonogestrel-releasing IUSDrug

    Low dose; treatment duration of 6 months with a possible extension to 12 months

  • Etonogestrel-releasing IUSDrug

    Intermediate dose; treatment duration of 6 months with a possible extension to 12 months

  • Etonogestrel-releasing IUSDrug

    High dose; treatment duration of 6 months with a possible extension to 12 months

  • Multiload-cu 375®Device

    Duration of 6 months with a possible extension to 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy outcome for the trial is insertion and removal characteristics, adverse event reporting and subject's satisfaction with the ENG-MIUSTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dinox GmbH

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.